Exacerbation in Glycemic Control by Switching from Subcutaneous Dulaglutide Injection to Oral Semaglutide Administration in a Patient with Type 2 Diabetes, Who Had Undergone Gastrectomy

Kohzo Takebayashi; Akira Harasawa; Yuki Miyake; Atsushi Ujiie; Mototaka Yamauchi; Kenji Hara; Takafumi Tsuchiya; Koshi Hashimoto

doi:10.51040/dkmj.2023-060

Case Report

Exacerbation in Glycemic Control by Switching from Subcutaneous Dulaglutide Injection to Oral Semaglutide Administration in a Patient with Type 2 Diabetes, Who Had Undergone Gastrectomy

Kohzo Takebayashi, Akira Harasawa, Yuki Miyake, Atsushi Ujiie, Mototaka Yamauchi, Kenji Hara, Takafumi Tsuchiya, Koshi Hashimoto

Author information

Kohzo Takebayashi
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Akira Harasawa
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Yuki Miyake
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Atsushi Ujiie
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Mototaka Yamauchi
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Kenji Hara
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Takafumi Tsuchiya
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
Koshi Hashimoto
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan

Keywords: oral semaglutide, dulaglutide, pyloric gastrectomy, type 2 diabetes

JOURNAL OPEN ACCESS

2024 Volume 3 Issue 4 Pages 303-307

DOI https://doi.org/10.51040/dkmj.2023-060

Browse “Advance online publication” version

Details

Abstract

We describe a case of an 83-year-old man with type 2 diabetes, who had undergone laparoscopy-assisted pyloric 2/3 gastrectomy 7 years ago. Switch from subcutaneous injection of dulaglutide, a glucagon-like protein-1(GLP-1) receptor agonist (GLP-1RA), to administration of oral semaglutide, another GLP-1RA, exacerbated his glycemic status. Because semaglutide is absorbed from the stomach, administration of oral semaglutide to patients after gastrectomy should be avoided even if the surgery is a partial gastrectomy.

Corresponding author

Register with J-STAGE for free!